Last updated on March 2019

A Phase 2, Dose-Escalation, Placebo-Controlled Study of the Safety of INCB054707 in Participants With Hidradenitis Suppurativa


Brief description of study

Primary end point: To determine the safety and tolerability of INCB054707.

Key Secondary end point: To determine the systemic exposure to INCB054707 and to determine the efficacy of INCB054707.

Overall design: Population: Men and women aged 18 to 75 years with moderate to severe HS for at least 6 months.

Number of Participants: The study includes 3 cohorts and approximately 36 participants will be enrolled. In each cohort, approximately 12 participants will be randomized 3:1 (INCB054707:placebo) to 1 of 2 treatment groups.

Study Design: Randomized, dose escalation, placebo-control

Estimated Duration of Study Participation: The study will consist of a screening period of up to 28 days, an 8-week treatment period, and a 30-day safety follow-up period. The estimated total duration of study participation is approximately 16 weeks for each participant.

Clinical Study Identifier: TX211866

Contact Investigators or Research Sites near you

Start Over

Marie-Pier Devost

DermEffects
London, Ontario Canada

Marie-Pier Devost

Windsor Clinical Research, Inc
Windsor, Ontario Canada

Marie-Pier Devost

Brunswick Dermatology Center
Fredericton, New Brunswick Canada

Marie-Pier Devost

York Dermatology Center
Richmond Hill, Ontario Canada

Marie-Pier Devost

Lynderm Research Inc.
Markham, Ontario Canada

Marie-Pier Devost

Dr Isabelle Delorme Inc.
Drummondville, Quebec Canada

Marie-Pier Devost

Dre Angelique Gagne-Henley MD inc.
St-Jerome, Quebec Canada

Marie-Pier Devost

SimcoDerm Medical and Surgical Dermatology Center
Barrie, Ontario Canada

Marie-Pier Devost

Wiseman Dermatology Research
Winnipeg, Manitoba Canada

Recruitment Status: Closed


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.